Highly bioavailable silibinin nanoparticles inhibit HCV infection

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Gut

• Publication date

  2016-07-19

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1136/gutjnl-2016-312019PMID 27436270
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Silymarin in the treatment of liver diseases: What is the clinical evidence?

  2016cited by this paper
• Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.

  2015cited by this paper
• Hepatitis C virus treatment in the real world: optimising treatment and access to therapies

  2015cited by this paper
• A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients

  2015cited by this paper
• Antiviral treatment of hepatitis C

  2014cited by this paper
• Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial

  2014cited by this paper
• Therapy for hepatitis C--the costs of success.

  2014cited by this paper
• Efficacy of lead‐in silibinin and subsequent triple therapy in difficult‐to‐treat HIV/hepatitis C virus‐coinfected patients

  2014cited by this paper
• Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B

  2013cited by this paper
• Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period.

  2013cited by this paper
• The ins and outs of hepatitis C virus entry and assembly

  2013cited by this paper
• Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry

  2013cited by this paper
• Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period.

  2013cited by this paper
• Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin‐dependent trafficking

  2013cited by this paper
• Solid Dispersions as Strategy to Improve Oral Bioavailability of Poor Water Soluble Drugs

  2013cited by this paper
• Current and future therapies for hepatitis C virus infection.

  2013cited by this paper
• Silibinin: an old drug in the high tech era of liver transplantation.

  2013cited by this paper
• Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.

  2012cited by this paper
• Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

  2012cited by this paper
• Understanding silibinin's modes of action against HCV using viral kinetic modeling.

  2012cited by this paper
• High‐dose silibinin rescue treatment for HCV‐infected patients showing suboptimal virologic response to standard combination therapy

  2012cited by this paper
• Characteristics and antioxidant activities of silymarin nanoparticles.

  2012cited by this paper
• Nanonization strategies for poorly water-soluble drugs.

  2011cited by this paper
• Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C

  2011cited by this paper
• Differential In Vitro Effects of Intravenous versus Oral Formulations of Silibinin on the HCV Life Cycle and Inflammation

  2011cited by this paper
• Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy.

  2011cited by this paper
• Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C.

  2011cited by this paper
• Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy.

  2010cited by this paper
• Identification of hepatoprotective flavonolignans from silymarin

  2010cited by this paper
• Author manuscript, published in "Gastroenterology 2010;138(3):1112-22" DOI: 10.1053/j.gastro.2009.11.053 SILIBININ AND RELATED COMPOUNDS ARE DIRECT INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE

  2010cited by this paper
• Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus

  2008cited by this paper
• Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

  2008cited by this paper
• Silybin and silymarin--new and emerging applications in medicine.

  2007cited by this paper
• Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.

  2007cited by this paper
• Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin.

  2007cited by this paper
• Antiviral treatment of hepatitis C

  2006cited by this paper
• Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication.

  2006cited by this paper
• Nanotechnology for the biologist

  2005cited by this paper
• Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms

  2004cited by this paper
• Hepatotoxicity and Mechanism of Action of Haloalkanes: Carbon Tetrachloride as a Toxicological Model

  2003cited by this paper
• Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention.

  1999cited by this paper
• Clinical Toxicology of Commercial Products

  1969cited by this paper
• Clinical Toxicology of Commercial Products

  1964cited by this paper

• Nanoparticle approaches for hepatitis therapy and clinical translation

  2026cites this paper
• Phytochemical-based nanosystems: recent advances and emerging application in antiviral photodynamic therapy.

  2025cites this paper
• Nanoparticles Based Therapeutic Approaches in Oncogenic Viral Infections: A Review

  2025cites this paper
• Current treatments and the future of nanomedicine in hepatitis C.

  2025cites this paper
• Silybin: A Review of Its Targeted and Novel Agents for Treating Liver Diseases Based on Pathogenesis

  2024cites this paper
• A Comprehensive Review on the Antibacterial, Antifungal, Antiviral, and Antiparasitic Potential of Silybin

  2024cites this paper
• Novel Strategies Enhancing Bioavailability and Therapeutical Potential of Silibinin for Treatment of Liver Disorders

  2024cites this paper
• Possible Uses for Silymarin in Human Health: Systematic Review

  2024cites this paper
• Specialized metabolites from plants as a source of new multi-target antiviral drugs: a systematic review

  2023cites this paper
• A comparative study on the preparation and evaluation of solubilizing systems for silymarin

  2023cites this paper
• Medicinal plant molecules against hepatitis C virus: Current status and future prospect

  2023cites this paper
• Protective role of flavonoids quercetin and silymarin in the viral-associated inflammatory bowel disease: an updated review

  2023cites this paper
• Increased therapeutic effect of nanotized silibinin against glycation and diabetes: An in vitro and in silico-based approach.

  2023cites this paper
• The novel hepatoprotective mechanisms of silibinin-phospholipid complex against d-GalN/LPS-induced acute liver injury.

  2023cites this paper
• Preclinical validation of silibinin/albumin nanoparticles as an applicable system against acute liver injury.

  2022cites this paper
• Antimicrobial benefits of flavonoids and their nanoformulations.

  2022cites this paper
• Silibinin ameliorates abrin induced hepatotoxicity by attenuating oxidative stress, inflammation and inhibiting Fas pathway.

  2022cites this paper
• Silibinin Therapy Improves Cholangiocarcinoma Outcomes by Regulating ERK/Mitochondrial Pathway

  2022cites this paper
• Magnetic-core-based silibinin nanopolymeric carriers for the treatment of renal cell cancer.

  2021cites this paper
• Ursolic Acid and Its Nanoparticles Are Potentiators of Oncolytic Measles Virotherapy against Breast Cancer Cells

  2021influential citation
• Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies.

  2021cites this paper
• Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin

  2021cites this paper
• Nano- and Microsized Forms of Silymarin and Silybin

  2021cites this paper
• Monodispersed magnetographene quantum dot nanocomposites for delivery of silibinin

  2021cites this paper
• Emerging nanoformulation strategies for phytocompounds and applications from drug delivery to phototherapy to imaging

  2021cites this paper
• Targeting Autophagy Augments Berberine-Mediated Cell Death in Human Hepatoma Cells Harboring Hepatitis C Virus RNA

  2020cites this paper
• Silibinin Induces G2/M Cell Cycle Arrest by Activating Drp1-Dependent Mitochondrial Fission in Cervical Cancer

  2020cites this paper
• Silymarin: not just another antioxidant

  2020cites this paper
• Silibinin Differentially Decreases the Aggressive Cancer Phenotype in an In Vitro Model of Obesity and Prostate Cancer

  2020cites this paper
• Drug Delivery Strategies for Poorly Water-Soluble Silymarin

  2020cites this paper
• Identification of the phytobioactive Polygonum cuspidatum as an antiviral source for restricting dengue virus entry

  2020cites this paper
• Combination drug therapy via nanocarriers against infectious diseases.

  2019cites this paper
• Silibinin Retards Colitis-associated Carcinogenesis by Repression of Cdc25C in Mouse Model.

  2019cites this paper
• Formulation Strategies for Enhancing the Bioavailability of Silymarin: The State of the Art

  2019cites this paper
• Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein.

  2019cites this paper
• Antiviral Activities of Silymarin and Derivatives

  2019cites this paper
• Nanomedicine as a future therapeutic approach for Hepatitis C virus.

  2019cites this paper
• Methanolic Extract of Rhizoma Coptidis Inhibits the Early Viral Entry Steps of Hepatitis C Virus Infection

  2018cites this paper
• Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases

  2018cites this paper
• Fabrication, characterization and in vitro evaluation of silibinin nanoparticles: an attempt to enhance its oral bioavailability

  2017cites this paper
• Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's disease.

  2017cites this paper
• Preparation, characterization and antitumor activity evaluation of silibinin nanoparticles for oral delivery through liquid antisolvent precipitation

  2017cites this paper
• Strategies to Preclude Hepatitis C Virus Entry

  2017cites this paper
• Fabrication, characterization and in vitro evaluation of silibinin nanoparticles: an attempt to enhance its oral bioavailability

  2017cites this paper
• Phytomedicine : Silybum marianum ( Silymarin ) as an Effective Hepato-protective Source from Nature

  year unknowncites this paper